|Day Low/High||10.48 / 10.68|
|52 Wk Low/High||6.25 / 13.76|
Without it, the uncertainty would be incredible between now and November.
Here are three recent examples of how the patient can profit.
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
AAP portfolio managers Cramer and Mohr defend the drug company after it tops analysts' bottom-line expectations while missing top-line estimates.
Rarely do investors get to buy these types of quality businesses at such discounted prices.
Deal rumors are deflating, but a takeover bid could reward holdouts.
An investor should make good money on any turn in the drug maker's business or in investor sentiment.
The drug maker is a compelling buy and has 50% upside potential over the next 18 to 24 months.
I made my second generational low call in seven years today. Peak Bonds. And a generational low in yields has possibly been reached. Peak Greed! Buyers live higher and sellers live lower in a marketplace dominated by machines and algos. Price moment...
They need to do something that makes them stand out as stocks you want to own, not avoid.
Tesla shares sink on delivery miss while Goldman Sachs looks to curb spending within its asset-management division.
The economy's fundamentals, as well as corporate earnings growth, look better now than at the beginning of the year.
Allergan shares are up slightly following news that activist investor Carl Icahn recently acquired a 'large position' in the pharmaceutical company.
We expect an upward revision in AGN's valuation multiple after the generics deal with Teva.
Allergan's stock may start to realize the potential already seen by several Real Money analysts and contributors.
Problems with mesh products and high leverage might scare away a potential buyer.
Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.
The company hit all the major points of investor concern.
The worldwide selloff in biotech stocks and the lack of performance by generic drug giant Teva has hampered Israeli stocks thus far in 2016.
Solid earnings and the start of some M&A activity may be just what this sector needs to rise.
If TEVA breaks below $50, then a longer-term decline could be in the cards.
This year's mix of Sohn speakers includes asset managers, a behavioral economist and two-time Super Bowl champ Eli Manning.